Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: In vitro comparison of two different point of care devices

Acta Anaesthesiologica Scandinavica

Volumn 50, Issue 4, 2006, Pages 461-468

  Dalbert, S ^a   Ganter, M T ^b   Furrer, L ^a   Klaghofer, R ^c   Zollinger, A ^a   Hofer, C K ^a  

^a TRIEMLI HOSPITAL   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Activated clotting time; Anticoagulation; Blood coagulation; Cardiopulmonary bypass; Heparin; Kaolin; Measurement techniques; Sonoclot analysis

Indexed keywords

APROTININ; HEPARIN; KAOLIN; RINGER LACTATE SOLUTION;

ANTICOAGULATION; ARTICLE; BLOOD CLOT; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; ELECTIVE SURGERY; HEART SURGERY; HEMODILUTION; HEPARINIZATION; HUMAN; PRIORITY JOURNAL;

ANTICOAGULANTS; APROTININ; BLOOD COAGULATION TESTS; CARDIAC SURGICAL PROCEDURES; HEMODILUTION; HEMOSTATICS; HEPARIN; HUMANS; ISOTONIC SOLUTIONS; KAOLIN; POINT-OF-CARE SYSTEMS; WHOLE BLOOD COAGULATION TIME;

EID: 33645225629     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2006.00990.x     Document Type: Article

References (25)

1. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966 196 436 40.
2. Bull BS Huse WM Brauer FS Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975 69 685 9.
3. Bull BS Korpman RA Huse WM Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975 69 674 84.
4. Wendel HP Heller W Gallimore MJ Bantel H Muller-Beissenhirtz H Hoffmeister HE. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis 1993 4 41 5.
5. Laurel MT Ratnoff OD Everson B. Inhibition of the activation of Hageman factor (factor XII) by aprotinin (Trasylol). J Lab Clin Med 1992 119 580 5.
6. Henry DA Moxey AJ Carless PA O' Connell D Mc Clelland B Henderson KM et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001 CD001886.
7. Smith PK Shah AS. The role of aprotinin in a blood-conservation program. J Cardiothorac Vasc Anesth 2004 18 S24 S28.
8. Despotis GJ Filos KS Levine V Alsoufiev A Spitznagel E. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Anesth Analg 1996 82 1126 31.
9. Jones K Nasrallah F Darling E Clay N Searles B. The in vitro effects of aprotinin on twelve different ACT tests. J Extra Corpor Technol 2004 36 51 7.
10. Hett DA Walker D Pilkington SN Smith DC. Sonoclot analysis. Br J Anaesth 1995 75 771 6.
11. Despotis GJ Gravlee G Filos K Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999 91 1122 51.
12. Prisco D Paniccia R. Point-of-care testing of hemostasis in cardiac surgery. Thromb J 2003 1 1.
13. Shore-Lesserson L. Monitoring anticoagulation and hemostasis in cardiac surgery. Anesthesiol Clin North America 2003 21 511 26.
14. Bland JM Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995 346 1085 7.
15. Despotis GJ Summerfield AL Joist JH et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994 108 1076 82.
16. Moorehead MT Westengard JC Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984 63 394 8.
17. Ganter MT Dalbert S Graves K Klaghofer R Zollinger A Hofer CK. Monitoring activated clotting time for combined heparin and aprotinin application: an in vitro evaluation of a new aprotinin-insensitive test using SONOCLOT. Anesth Analg 2005 101 308 14.
18. Koster A Fischer T Praus M et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002 97 837 41.
19. Konrad C Markl T Schuepfer G Gerber H Tschopp M. The effects of in vitro hemodilution with gelatin, hydroxyethyl starch, and lactated Ringer's solution on markers of coagulation: an analysis using SONOCLOT. Anesth Analg 1999 88 483 8.
20. Konrad CJ Markl TJ Schuepfer GK Schmeck J Gerber HR. In vitro effects of different medium molecular hydroxyethyl starch solutions and lactated Ringer's solution on coagulation using SONOCLOT. Anesth Analg 2000 90 274 9.
21. Ruttmann TG James MF Aronson I. In vivo investigation into the effects of haemodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation. Br J Anaesth 1998 80 612 6.
22. Dietrich W Jochum M. Effect of celite and kaolin on activated clotting time in the presence of aprotinin: activated clotting time is reduced by binding of aprotinin to kaolin. J Thorac Cardiovasc Surg 1995 109 177 8.
23. Swartz MF Fink GW Searles B. Aprotinin and hemostasis monitoring concerns during cardiac surgery. J Extra Corpor Technol 2004 36 375 83.
24. Dietrich W Dilthey G Spannagl M Jochum M Braun SL Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Anesthesiology 1995 83 679 89.
25. Kmiecik SA Liu JL Vaadia TS et al. Quantitative evaluation of hypothermia, hyperthermia, and hemodilution on coagulation. J Extra Corpor Technol 2001 33 100 5.